Back to Library
Weight LossMetabolic Health

Cagrilintide

Amylin analogue for stacking with Tirzepatide/Retatrutide

Overview

Cagrilintide is a long-acting acylated analogue of the pancreatic hormone amylin. It is designed for once-weekly administration to promote profound satiety and slow gastric emptying. In advanced metabolic research, it is now primarily investigated as the 'perfect partner' for multi-receptor agonists like Tirzepatide and Retatrutide. While these agonists drive metabolic rate and insulin sensitivity, Cagrilintide provides the 'mechanical' fullness signal, creating a synergistic effect for maximum weight loss.

Chemical Information

IUPAC Name
Acylated Amylin Analogue
Sequence
Modified Amylin Sequence (Acylated)
Molecular Mass
4498.0 Da
Formula
C194H312N52O63
Cagrilintide Chemical Structure

Mechanism of Action

Functions as a long-acting Amylin Receptor agonist. Its primary role is Gastric Braking: it physically slows down the rate at which food leaves the stomach, prolonging the feeling of fullness. This makes it the ideal stack for Tirzepatide (GLP-1/GIP) or Retatrutide (GLP-1/GIP/Glucagon). While Tirzepatide/Retatrutide handle the metabolic side (burning fat/improving insulin), Cagrilintide handles the behavioral side (stopping the urge to eat). By combining an Amylin agonist with a GLP-1/GIP/Glucagon agonist, research shows a 'multi-modal' attack on obesity: mechanical satiety + metabolic acceleration + hormonal optimization.

Potential Research Fields

ObesityCombination with TirzepatideCombination with RetatrutideGastric EmptyingSatiety Signaling

Recent Research

Current 2024-2025 research is focused on 'Combinatorial Obesity Therapy.' Investigators are finding that pairing Cagrilintide (Amylin) with dual/triple agonists like Tirzepatide or Retatrutide yields superior results to any single agent. While Tirzepatide/Retatrutide increase energy expenditure (thermogenesis) and improve insulin sensitivity, they do not always fully arrest gastric motility. Adding Cagrilintide fills this gap by forcefully slowing digestion. Early data suggests this 'Amylin + Multi-Agonist' stack may offer the highest ceiling for non-surgical weight loss, effectively combining hormonal metabolic boosting with mechanical appetite suppression.

Bibliography / Scientific References

Related Peptides

Research
SLU-PP-332

Exercise mimetic for mitochondrial biogenesis and fat loss

Research
5-Amino-1MQ

NNMT inhibitor for fat loss and NAD+ restoration

Peptide Information Guide
Administration Type
Injectable (Subcutaneous)

Injectable administration protocol for research.

Vial Strength
10mg
Reconstitution
Reconstitute with 2ml Physiological Solution (Saline)
Dosage Options
0.5 mg (10 units)
1x Week
Protocol for 10mg/2ml. (Conc: 5mg/ml. 10u=0.1ml=0.5mg).
0.75 mg (15 units)
1x Week
Protocol for 10mg/2ml. (Conc: 5mg/ml. 15u=0.15ml=0.75mg).
Schedule
1x Per Week
Timing: One specific day.
Duration
According to the Doctor
Potential Side Effects
Nausea
highvery common
Decreased appetite
highexpected effect
Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.